



Thomas Weisel Partners Healthcare Tailwinds Conference to Webcast Alkermes' Corporate Presentation

August 26, 2004

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 26, 2004--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate update will be webcast live by Thomas Weisel on Friday, September 10, 2004 at 8:00am EDT. The presentation will be webcast from The Four Seasons Hotel in Boston and may be accessed under the investor relation's tab at www.alkermes.com. The presentation will be archived for 14 days.

Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company's lead commercial product, Risperdal(R) Consta(TM) ((risperidone) long-acting injection), is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag, a division of Johnson & Johnson. The Company's lead proprietary product candidate, Vivitrex(R) ((naltrexone) long-acting injection), is a once-a-month injection for the treatment of alcohol dependence. Alkermes has a pipeline of extended-release injectable and pulmonary drug products based on its proprietary technology and expertise. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

CONTACT: Rebecca Peterson
Director, Corporate Communications
Alkermes, Inc.
(617) 583-6378

SOURCE: Alkermes, Inc.